Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis
CONCLUSION: Our findings indicate that rather than BCR-depletion it is repopulation with unmutated BCRs, possibly from naïve B cells, which induces remission. This suggests that (pre-existing) differences in B-cell turnover between patients explain the interindividual differences in early clinical effect.PMID:38493208 | DOI:10.1186/s13075-024-03297-7 (Source: Cell Research)
Source: Cell Research - March 17, 2024 Category: Cytology Authors: Sabrina Pollastro Anne Musters Giulia Balzaretti Ilse Niewold Barbera van Schaik Signe H ässler Catharina M Verhoef Marc Pallardy Antoine van Kampen Xavier Mariette Niek de Vries ABIRISK Consortium Source Type: research
SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024
Clin Lymphoma Myeloma Leuk. 2024 Feb 22:S2152-2650(24)00082-X. doi: 10.1016/j.clml.2024.02.010. Online ahead of print.ABSTRACTProgress in mantle cell lymphoma (MCL) has led to significant improvement in outcomes of patients even in the real world (RW) setting albeit to a lesser degree. In parallel to the demonstration of benefit using combination therapy with rituximab plus high-dose cytarabine (R-AraC) as well as dose intensive therapy-autologous stem cell transplantation (DIT-ASCT) consolidation and maintenance, it became clear over the last 2 decades that MCL is a highly heterogenous disease at the molecular level, expl...
Source: Clinical Lymphoma and Myeloma - March 16, 2024 Category: Cancer & Oncology Authors: Andrew Ip Alexandra Della Pia Andre H Goy Source Type: research
Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL
Biomed Pharmacother. 2024 Mar 15;173:116386. doi: 10.1016/j.biopha.2024.116386. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL), a heterogeneous lymphoid malignancy, poses a significant threat to human health. The standard therapeutic regimen for patients with DLBCL is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), with a typical cure rate of 50-70%. However, some patients either relapse after complete remission (CR) or exhibit resistance to R-CHOP treatment. Therefore, novel therapeutic approaches are imperative for managing high-risk or refractory DLBCL. Ferroptosis is...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 16, 2024 Category: Drugs & Pharmacology Authors: Wenxia Bian Haoran Li Yuhan Chen Yanhua Yu Guojie Lei Xinyi Yang Sainan Li Xi Chen Huanjuan Li Jing Yang Chen Yang Yanchun Li Yi Zhou Source Type: research
SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024
Clin Lymphoma Myeloma Leuk. 2024 Feb 22:S2152-2650(24)00082-X. doi: 10.1016/j.clml.2024.02.010. Online ahead of print.ABSTRACTProgress in mantle cell lymphoma (MCL) has led to significant improvement in outcomes of patients even in the real world (RW) setting albeit to a lesser degree. In parallel to the demonstration of benefit using combination therapy with rituximab plus high-dose cytarabine (R-AraC) as well as dose intensive therapy-autologous stem cell transplantation (DIT-ASCT) consolidation and maintenance, it became clear over the last 2 decades that MCL is a highly heterogenous disease at the molecular level, expl...
Source: Clinical Lymphoma and Myeloma - March 16, 2024 Category: Cancer & Oncology Authors: Andrew Ip Alexandra Della Pia Andre H Goy Source Type: research
Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL
Biomed Pharmacother. 2024 Mar 15;173:116386. doi: 10.1016/j.biopha.2024.116386. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL), a heterogeneous lymphoid malignancy, poses a significant threat to human health. The standard therapeutic regimen for patients with DLBCL is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), with a typical cure rate of 50-70%. However, some patients either relapse after complete remission (CR) or exhibit resistance to R-CHOP treatment. Therefore, novel therapeutic approaches are imperative for managing high-risk or refractory DLBCL. Ferroptosis is...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 16, 2024 Category: Drugs & Pharmacology Authors: Wenxia Bian Haoran Li Yuhan Chen Yanhua Yu Guojie Lei Xinyi Yang Sainan Li Xi Chen Huanjuan Li Jing Yang Chen Yang Yanchun Li Yi Zhou Source Type: research
Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis
Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself. (Source: Arthritis Research and Therapy)
Source: Arthritis Research and Therapy - March 16, 2024 Category: Rheumatology Authors: Sabrina Pollastro, Anne Musters, Giulia Balzaretti, Ilse Niewold, Barbera van Schaik, Signe H ässler, Catharina M. Verhoef, Marc Pallardy, Antoine van Kampen, Xavier Mariette and Niek de Vries Tags: Research Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP)
CONCLUSION: CTLA-4 CT 60 A/G may affect the susceptibility of ITP, but both CTLA-4 + 49 A/G and CT60 A/G did not impact the response of patients with ITP to different lines of therapy.PMID:38485815 | DOI:10.1007/s44313-024-00011-z (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Doaa Mohamed El Demerdash Maha Mohamed Saber Alia Ayad Kareeman Gomaa Mohamed Abdelkader Morad Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | DOI:10.1007/s44313-024-00006-w (Source: Cell Research)
Source: Cell Research - March 15, 2024 Category: Cytology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP)
CONCLUSION: CTLA-4 CT 60 A/G may affect the susceptibility of ITP, but both CTLA-4 + 49 A/G and CT60 A/G did not impact the response of patients with ITP to different lines of therapy.PMID:38485815 | PMC:PMC10917709 | DOI:10.1007/s44313-024-00011-z (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Doaa Mohamed El Demerdash Maha Mohamed Saber Alia Ayad Kareeman Gomaa Mohamed Abdelkader Morad Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
